UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Thyroid function in nonthyroidal illness

Author
Douglas S Ross, MD
Section Editor
David S Cooper, MD
Deputy Editor
Jean E Mulder, MD

INTRODUCTION

Assessment of thyroid function in patients with nonthyroidal illness is difficult, especially among those hospitalized in an intensive care unit (ICU). Many of them have low serum concentrations of both thyroxine (T4) and triiodothyronine (T3) and their serum thyroid-stimulating hormone (TSH) concentration also may be low. Previously, these patients were thought to be euthyroid, and the term euthyroid-sick syndrome was used to describe the laboratory abnormalities [1]. However, there is evidence that these patients may have acquired transient central hypothyroidism [1].

Despite these abnormalities, treatment of these patients with thyroid hormone, while controversial, appears to be of little benefit, and may be harmful [2]. It is possible that the changes in thyroid function during severe illness are protective in that they prevent excessive tissue catabolism [2].

This topic will review the changes in thyroid hormone and TSH metabolism that can occur in patients with nonthyroidal illness. The utility of the different tests to assess thyroid function is discussed separately. (See "Laboratory assessment of thyroid function".)

There are two important general principles [3]:

Thyroid function should not be assessed in seriously ill patients unless there is a strong suspicion of thyroid dysfunction.

                          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Nov 03 00:00:00 GMT 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Chopra IJ. Clinical review 86: Euthyroid sick syndrome: is it a misnomer? J Clin Endocrinol Metab 1997; 82:329.
  2. Utiger RD. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med 1995; 333:1562.
  3. Stockigt JR. Guidelines for diagnosis and monitoring of thyroid disease: nonthyroidal illness. Clin Chem 1996; 42:188.
  4. Davidson MB, Chopra IJ. Effect of carbohydrate and noncarbohydrate sources of calories on plasma 3,5,3'-triiodothyronine concentrations in man. J Clin Endocrinol Metab 1979; 48:577.
  5. Peeters RP, Wouters PJ, Kaptein E, et al. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab 2003; 88:3202.
  6. Peeters RP, Wouters PJ, van Toor H, et al. Serum 3,3',5'-triiodothyronine (rT3) and 3,5,3'-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. J Clin Endocrinol Metab 2005; 90:4559.
  7. Peeters RP, Kester MH, Wouters PJ, et al. Increased thyroxine sulfate levels in critically ill patients as a result of a decreased hepatic type I deiodinase activity. J Clin Endocrinol Metab 2005; 90:6460.
  8. Arem R, Wiener GJ, Kaplan SG, et al. Reduced tissue thyroid hormone levels in fatal illness. Metabolism 1993; 42:1102.
  9. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41:911.
  10. Chopra IJ, Huang TS, Beredo A, et al. Evidence for an inhibitor of extrathyroidal conversion of thyroxine to 3,5,3'-triiodothyronine in sera of patients with nonthyroidal illnesses. J Clin Endocrinol Metab 1985; 60:666.
  11. van der Poll T, Romijn JA, Wiersinga WM, Sauerwein HP. Tumor necrosis factor: a putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 1990; 71:1567.
  12. Stouthard JM, van der Poll T, Endert E, et al. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. J Clin Endocrinol Metab 1994; 79:1342.
  13. Corssmit EP, Heyligenberg R, Endert E, et al. Acute effects of interferon-alpha administration on thyroid hormone metabolism in healthy men. J Clin Endocrinol Metab 1995; 80:3140.
  14. Nagaya T, Fujieda M, Otsuka G, et al. A potential role of activated NF-kappa B in the pathogenesis of euthyroid sick syndrome. J Clin Invest 2000; 106:393.
  15. Vos RA, De Jong M, Bernard BF, et al. Impaired thyroxine and 3,5,3'-triiodothyronine handling by rat hepatocytes in the presence of serum of patients with nonthyroidal illness. J Clin Endocrinol Metab 1995; 80:2364.
  16. Chopra IJ. An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man. J Clin Invest 1976; 58:32.
  17. Kaptein EM, Feinstein EI, Nicoloff JT, Massry SG. Serum reverse triiodothyronine and thyroxine kinetics in patients with chronic renal failure. J Clin Endocrinol Metab 1983; 57:181.
  18. Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev 1996; 17:45.
  19. LoPresti JS, Fried JC, Spencer CA, Nicoloff JT. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:970.
  20. Ricart-Engel W, Fernández-Real JM, González-Huix F, et al. The relation between thyroid function and nutritional status in HIV-infected patients. Clin Endocrinol (Oxf) 1996; 44:53.
  21. Burmeister LA. Reverse T3 does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome. Thyroid 1995; 5:435.
  22. Jirasakuldech B, Schussler GC, Yap MG, et al. A characteristic serpin cleavage product of thyroxine-binding globulin appears in sepsis sera. J Clin Endocrinol Metab 2000; 85:3996.
  23. Chopra IJ, Solomon DH, Hepner GW, Morgenstein AA. Misleadingly low free thyroxine index and usefulness of reverse triiodothyronine measurement in nonthyroidal illnesses. Ann Intern Med 1979; 90:905.
  24. Stockigt J. Assessment of thyroid function: towards an integrated laboratory--clinical approach. Clin Biochem Rev 2003; 24:109.
  25. Wong TK, Pekary AE, Hoo GS, et al. Comparison of methods for measuring free thyroxin in nonthyroidal illness. Clin Chem 1992; 38:720.
  26. Docter R, Krenning EP, de Jong M, Hennemann G. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol (Oxf) 1993; 39:499.
  27. Chopra IJ. Simultaneous measurement of free thyroxine and free 3,5,3'-triiodothyronine in undiluted serum by direct equilibrium dialysis/radioimmunoassay: evidence that free triiodothyronine and free thyroxine are normal in many patients with the low triiodothyronine syndrome. Thyroid 1998; 8:249.
  28. Chopra IJ, Teco GN, Mead JF, et al. Relationship between serum free fatty acids and thyroid hormone binding inhibitor in nonthyroid illnesses. J Clin Endocrinol Metab 1985; 60:980.
  29. Lim CF, Bernard BF, de Jong M, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993; 76:318.
  30. Lim CF, Curtis AJ, Barlow JW, et al. Interactions between oleic acid and drug competitors influence specific binding of thyroxine in serum. J Clin Endocrinol Metab 1991; 73:1106.
  31. Mendel CM, Frost PH, Cavalieri RR. Effect of free fatty acids on the concentration of free thyroxine in human serum: the role of albumin. J Clin Endocrinol Metab 1986; 63:1394.
  32. Mendel CM, Laughton CW, McMahon FA, Cavalieri RR. Inability to detect an inhibitor of thyroxine-serum protein binding in sera from patients with nonthyroid illness. Metabolism 1991; 40:491.
  33. Oppenheimer JH, Schwartz HL, Mariash CN, Kaiser FE. Evidence for a factor in the sera of patients with nonthyroidal disease which inhibits iodothyronine binding by solid matrices, serum proteins, and rat hepatocytes. J Clin Endocrinol Metab 1982; 54:757.
  34. Wehmann RE, Gregerman RI, Burns WH, et al. Suppression of thyrotropin in the low-thyroxine state of severe nonthyroidal illness. N Engl J Med 1985; 312:546.
  35. Hamblin PS, Dyer SA, Mohr VS, et al. Relationship between thyrotropin and thyroxine changes during recovery from severe hypothyroxinemia of critical illness. J Clin Endocrinol Metab 1986; 62:717.
  36. Romijn JA, Wiersinga WM. Decreased nocturnal surge of thyrotropin in nonthyroidal illness. J Clin Endocrinol Metab 1990; 70:35.
  37. Lee HY, Suhl J, Pekary AE, Hershman JM. Secretion of thyrotropin with reduced concanavalin-A-binding activity in patients with severe nonthyroid illness. J Clin Endocrinol Metab 1987; 65:942.
  38. Persani L, Ferretti E, Borgato S, et al. Circulating thyrotropin bioactivity in sporadic central hypothyroidism. J Clin Endocrinol Metab 2000; 85:3631.
  39. Fliers E, Guldenaar SE, Wiersinga WM, Swaab DF. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. J Clin Endocrinol Metab 1997; 82:4032.
  40. Van den Berghe G, Wouters P, Weekers F, et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. J Clin Endocrinol Metab 1999; 84:1311.
  41. Fliers E, Bianco AC, Langouche L, Boelen A. Thyroid function in critically ill patients. Lancet Diabetes Endocrinol 2015; 3:816.
  42. Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990; 70:453.
  43. Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients: a systematic review. Arch Intern Med 1999; 159:658.
  44. Spratt DI, Pont A, Miller MB, et al. Hyperthyroxinemia in patients with acute psychiatric disorders. Am J Med 1982; 73:41.
  45. Chopra IJ, Solomon DH, Huang TS. Serum thyrotropin in hospitalized psychiatric patients: evidence for hyperthyrotropinemia as measured by an ultrasensitive thyrotropin assay. Metabolism 1990; 39:538.
  46. Roca RP, Blackman MR, Ackerley MB, et al. Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism. Endocr Res 1990; 16:415.
  47. Slag MF, Morley JE, Elson MK, et al. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA 1981; 245:43.
  48. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. N Engl J Med 2011; 365:506.
  49. Langouche L, Vander Perre S, Marques M, et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomized, controlled clinical study. J Clin Endocrinol Metab 2013; 98:1006.
  50. Vignati L, Finley RJ, Hagg S, Aoki TT. Protein conservation during prolonged fast: a function of triiodothyronine levels. Trans Assoc Am Physicians 1978; 91:169.
  51. Gardner DF, Kaplan MM, Stanley CA, Utiger RD. Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. N Engl J Med 1979; 300:579.
  52. Becker RA, Vaughan GM, Ziegler MG, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med 1982; 10:870.
  53. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986; 63:1.
  54. Broderick TJ, Wechsler AS. Triiodothyronine in cardiac surgery. Thyroid 1997; 7:133.
  55. Novitzky D, Fontanet H, Snyder M, et al. Impact of triiodothyronine on the survival of high-risk patients undergoing open heart surgery. Cardiology 1996; 87:509.
  56. Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med 1995; 333:1522.
  57. Bennett-Guerrero E, Jimenez JL, White WD, et al. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery. A randomized, double-blind, placebo- controlled trial. Duke T3 study group. JAMA 1996; 275:687.
  58. Spratt DI, Frohnauer M, Cyr-Alves H, et al. Physiological effects of nonthyroidal illness syndrome in patients after cardiac surgery. Am J Physiol Endocrinol Metab 2007; 293:E310.
  59. Kaptein EM, Sanchez A, Beale E, Chan LS. Clinical review: Thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic review and synthesis. J Clin Endocrinol Metab 2010; 95:4526.
  60. Choi YS, Shim JK, Song JW, et al. Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting. J Cardiothorac Vasc Anesth 2013; 27:1218.
  61. Vidart J, Wajner SM, Leite RS, et al. N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial. J Clin Endocrinol Metab 2014; 99:4537.